SyntheX

SyntheX is expanding drug design into the ‘undruggable’ space for the treatment of cancer and rare diseases. We implement an innovative platform for the accelerated discovery of new classes of therapeutics that target the Achilles’ heel of cancer cells in a highly specific and selective manner.

Traditional drugs work by disrupting the enzymatic function of proteins. At SyntheX, we are expanding the drug discovery space from active site inhibitors to protein-protein interaction modulators using our innovative screening technology.

REQUEST INTRODUCTION USING

LINKEDIN ANGELLIST

COMPANY PEOPLE

Charly Chahwan

Charly Chahwan
Co Founder, CSO at SyntheX, Inc.

Maria Soloveychik

Maria Soloveychik
Co-founder, CEO at SyntheX, Inc.

YOU MIGHT ALSO BE INTERESTED IN